NCT00492167View on ClinicalTrials.gov

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 9, 2005

Primary Completion Date

March 4, 2022

Study Completion Date

March 4, 2022

Conditions
Neuroblastoma
Interventions
BIOLOGICAL

beta-glucan

BIOLOGICAL

monoclonal antibody 3F8

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00492167 - Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma | Biotech Hunter | Biotech Hunter